Introduce a novel post-biotic against Pseudomonas aeruginosa biofilm formation using Escherchia coli Nissle1917 outer membrane vesicles.
EcN
OMVs
PpyR
Pseudomonas aeruginosa
algD
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
09 Sep 2023
09 Sep 2023
Historique:
received:
19
11
2022
accepted:
06
09
2023
medline:
11
9
2023
pubmed:
10
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Pseudomonas aeruginosa is an opportunistic bacterial pathogen that can cause acute infections as well as chronic ones in humans. The expression of algD and PpyR genes involved in biofilm formation in clinical isolates of P. aeruginosa in the presence of Escherichia coli Nissle1917 outer membranes vesicles (EcN OMVs) was evaluated. All isolates were tested for biofilm formation. qPCR and disk diffusion were used to identify the expression of algD and PpyR genes, and antimicrobial resistance, respectively. EcN OMVs caused a more significant loss of algD and PpyR expression, compared with the control group. EcN OMVs contain a variety of biomolecules that are capable of influencing the biofilm formation genes. EcN OMVs treatment reduced P. aeruginosa biofilm formation significantly, which emphasizes their positive role in inhibiting biofilm formation. As a result, EcN OMVs can be used as new therapeutic strategies for inhibiting P. aeruginosa biofilm formation.
Identifiants
pubmed: 37689727
doi: 10.1186/s13104-023-06504-x
pii: 10.1186/s13104-023-06504-x
pmc: PMC10493014
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
201Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMC Microbiol. 2021 Aug 24;21(1):234
pubmed: 34429066
J Coll Physicians Surg Pak. 2011 Sep;21(9):531-4
pubmed: 21914408
Nutrients. 2020 Jul 23;12(8):
pubmed: 32717965
Clin Microbiol Infect. 2007 Jun;13(6):560-78
pubmed: 17266725
Microb Biotechnol. 2008 Jan;1(1):17-29
pubmed: 21261818
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1676-86
pubmed: 26711774
Clin Orthop Relat Res. 2005 Aug;(437):41-7
pubmed: 16056024
Infect Drug Resist. 2020 Feb 26;13:659-672
pubmed: 32161474
FEMS Microbiol Lett. 2005 Feb 1;243(1):271-8
pubmed: 15668029
BMC Infect Dis. 2018 Oct 5;18(1):507
pubmed: 30290773
Nat Commun. 2017 Sep 20;8(1):626
pubmed: 28931823
Adv Exp Med Biol. 2019;1125:37-45
pubmed: 30656552
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Biomed Res Int. 2022 May 24;2022:1716087
pubmed: 35655484
PLoS One. 2013;8(1):e54617
pubmed: 23382926
Nat Commun. 2016 Nov 07;7:13443
pubmed: 27819653
Mol Microbiol. 2004 Feb;51(3):675-90
pubmed: 14731271
PeerJ. 2019 Jan 22;7:e6217
pubmed: 30697478
Front Cell Infect Microbiol. 2015 Jan 28;5:1
pubmed: 25674541
Biomaterials. 2017 Jan;113:68-79
pubmed: 27810643
Int J Mol Sci. 2020 Nov 17;21(22):
pubmed: 33212950
PLoS One. 2012;7(11):e50214
pubmed: 23189190
Int J Microbiol. 2022 Oct 25;2022:6435774
pubmed: 36329896
BMC Res Notes. 2020 Jan 10;13(1):27
pubmed: 31924268
Infect Immun. 2011 Jun;79(6):2182-92
pubmed: 21464085
IDCases. 2015 Feb 11;2(2):40-3
pubmed: 26793451